Subsequently, MWHT was offered only to patients with high-risk features: young patients’ age (<50 years), high-grade invasive tumors (G3), adjacent to invasive ductal carcinoma in situ (DCIS), positive nodal status, close or positive surgical margins, indications for chemotherapy, perineural invasion (PNI), lymphovascular invasion (LVI), triple-negative BC (TNBC), and HER2-positive BC. Here, ERBB2 is linked to ductal breast carcinoma in situ.